Should it stay or should it IPO? That’s the question facing inVentiv owner Thomas H. Lee Partners as it weighs up potential bids from two buyout firms--while also mulling over going public.
This is according to sources talking to Reuters, who say Advent International and CVC Capital Partners “have made offers to acquire” inVentiv Group Holdings, the parent company of biopharma services provider inVentiv Health.
But a SEC report filed in April by inVentiv shows it is looking to gun for an IPO, with the company having a valuation of “over $4 billion” including debt, people familiar with the matter told the news wire service. The company was not commenting on the story.
A decision, the sources said, will be made by next week, and if an IPO is chosen, the company will look to go public next month. An IPO of $100 million was first spoken of, though analysts believe this could be bumped up to $500 million.
Last year, InVentiv reported net revenue of $2 billion, up 10% from the before-year period.
- check out the Reuters story
InVentiv to go public, hopes to raise $500M